Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose·2019·Obesity
DOI 10.1002/oby.22344

Cited by (256)

Items 201–256 of 256

  1. Lipid Metabolic Disorders: a Pivotal Driver in Type 2 Diabetes Mellitus Pathogenesis
    Junqi Wu, Huabin Wang, Miao Fu, Meili Zhang, Guigfang Zhao, Beiwei Yu · 2026 · Current Obesity Reports
  2. Hormones that are involved in metabolic homeostasis: Overview of the past century and future perspectives
    Jia Nuo Feng, Tianru Jin · 2022 · Obesity Medicine
  3. Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021
    Qin-Ying She, Lijuan Li, Ming-Hong Liu, Ru-Yu Tan, Yi-Wen Zhong, Jing‐Fu Bao, Jie-Dong Xie · 2022 · Frontiers in Pharmacology
  4. Computer-aided engineering of stabilized fibroblast growth factor 21
    Gabin de La Bourdonnaye, Tereza Ghazalova, Petr Fojtík, Kateřina Kutálková, David Bednář, Jiřı́ Damborský, Vladimír Rotrekl, Veronika Štěpánková, Radka Chaloupková · 2024 · Computational and Structural Biotechnology Journal
  5. Many roads lead to Rome: The FGF4–AMP‐activated protein kinase–Caspase 6 signal axis in NAFLD and NASH
    Alena Laschtowitz, Frank Tacke · 2022 · Hepatology
  6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long‐Acting FGF21 Analog Zalfermin
    Kirsten Dahl, Martin Haljeta Friedrichsen, Rasmus Ribel‐Madsen, Jakob Schiøler Hansen, Jesper O. Clausen, Mads Buhl Axelsen, Mads Sundby Palle, Solvej Lund Lippert, Olle Björkdahl, Søren Toubro et al. · 2025 · Clinical and Translational Science
  7. Emerging natural products against obesity and metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Direct target discovery and mechanistic insights
    Wei Hu, Meng Gu, Huibo Li, He Li, Juntao Kan, Lingli Zhang, Qian Ding, Zhu YZ · 2026 · Pharmacological Reviews
  8. The role of fibroblast growth factor 21 in diabetes and metabolic dysfunction
    Ashirvad Jaiswal, Chadani Nigam, Gaurish Narayan Singh, Anurag Kumar Gautam · 2026 · Molecular Biology Reports
  9. FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
    Ewa Szczepańska, Piotr Glinicki, Wojciech Zgliczyński, Jadwiga Slowinska-Srzednicka, Helena Jastrzębska, Małgorzata Gietka‐Czernel · 2022 · Frontiers in Endocrinology
  10. How far are we from an approved drug for nonalcoholic steatohepatitis?
    Nahúm Méndez‐Sánchez, Shreya C. Pal, Jacqueline Córdova‐Gallardo · 2023 · Expert Opinion on Pharmacotherapy
  11. Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism
    Zhenning Yang, Helmut Zarbl, Grace Liejun Guo · 2024 · Molecular Pharmacology
  12. Nuclear Receptors in Energy Metabolism
    Alina A. Walth-Hummel, Stephan Herzig, Maria Rohm · 2022 · Advances in experimental medicine and biology
  13. Pegbelfermin for reducing transaminase levels in patients with non-alcoholic steatohepatitis: a dose-response meta-analysis of randomized controlled trials
    Yangguang Lu, Bohuai Yu, Yiran Bu, Jialing Lou, Yan Jin · 2024 · Frontiers in Medicine
  14. Current and Emerging Treatments for Non-alcoholic Steatohepatitis
    Christian L. Horn, Anvi C. Ta, Nadege Gunn · 2020 · Current Hepatology Reports
  15. Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions
    Özge Besci, Merve Çelik Güler, Maria Cristina Foss‐Freitas, Elif A Oral · 2025 · Expert Review of Endocrinology & Metabolism
  16. Liver–pancreas communication in disease and drug development
    Yan Jia, Qingtian Zhu, Qiong Pan, Guotao Lu, Jia Xiao · 2026 · Acta Pharmaceutica Sinica B
  17. Pharmacology of NASH
    Somaya A. M. Albhaisi, Arun Jayant Sanyal · 2021 · Elsevier eBooks
  18. Next-Generation Therapies for Type 2 Diabetes Mellitus
    Debarun Patra, Soumyajit Roy, Palla Ramprasad, Durba Pal · 2024 · Smart nanomaterials technology
  19. Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes Mellitus
    Unnati Jain, Priyanka Srivastava, Ashwani Sharma, Subrata Sinha, Surabhi Johari · 2024 · Current Diabetes Reviews
  20. Deciphering the therapeutic efficacy of FGF19 and FGF21 in NAFLD: A comparative genomic and metabolic analysis
    Lengyun Wei, Pengpeng Long, Xianlong Ye, Shenglong Zhu, Siyuan Cui · 2024 · Food Bioscience
  21. Non-classical hormones from the fibroblast growth factor family
    Sofia Gronskaia, N. V. Rusyaeva, Zhanna E. Belaya, Galina Afanas'evna Mel'nichenko · 2024 · Problems of Endocrinology
  22. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration
    Beniamino Palmieri, Veronica Corazzari, Diana G. PANARIELLO BRASILE, Vincenzo Sangiovanni, Maria VADALÀ · 2021 · Minerva Gastroenterologica e Dietologica
  23. The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice
    J. Jose Corbalan, Brenda A. Petronella, Chia‐Yu Huang, James R. Beasley, J. Robert Merritt, B Mugrage, Joseph T. Nickels · 2025 · Biochemical and Biophysical Research Communications
  24. ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress
    Yuanzhen Zhang, Xiaozhi Hu, Zhonglian Cao, Kaicheng Zhou, Yun Sun, Yong Deng, Shuwen Xu, Yanyang Nan, Xi Gai, Mengyang Li et al. · 2025 · International Journal of Biological Macromolecules
  25. Fibroblast Growth Factor 21: Possible Role in Growth and Metabolic Development during Early Life, Nutritional Interactions and Biological Actions
    Jibran A. Wali, Jose M Ramos-Nieves, Aristea Binia, Eline M. van der Beek · 2026 · Advances in Nutrition
  26. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
    Pankaj Aggarwal, Tamneet Singh, Naim Alkhouri · 2020 · Current Hepatology Reports
  27. Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort
    Rui Zhang, Yufeng Li, Xianghai Zhou, Fang Zhang, Meng Li, Simin Zhang, Xiuying Zhang, Xin Wen, Linong Ji · 2021 · Medicine
  28. The Efficacy of Pharmacotherapy in the Treatment of Obesity in Patients With Type 2 Diabetes: A Systematic Review
    Omar Aodah S. Alshahrani, Mohammed S Almalki · 2024 · Cureus
  29. Fibroblast growth factor 21: a novel link in the development and treatment of metabolic disorders
    A. A. Mikhailova, Marina V. Sharypova, А. В. Симаненкова, Yu. V. Cheburkin, Фукс Оксана Станиславовна, Н. В. Тимкина, Vyacheslav A. Dyachuk, Т. Л. Каронова · 2025 · Arterial’naya Gipertenziya (Arterial Hypertension)
  30. Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
    Mohsina F. Patwekar, Faheem Patwekar, J. Pavan Kumar, P. Dharani Prasad, Nazia Malik, A. Venkata Badarinath, Prashanth Reddy Parupathi, Konatham Teja Kumar Reddy, Selvaraja Elumalai, Zainul Abedeen Ab Samad · 2025 · BIO Integration
  31. Drug Pipeline for Obesity Therapy
    Azania T. Panicker, Priyanshi S. Desai, Sanika Sanjay Karnik, Maushmi Shailesh Kumar · 2020 · Springer eBooks
  32. Paracrine Fibroblast Growth Factor-Based Therapy: An Unexpected Panacea for Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Tong-Tong Pan, Ting Li, Lumin Shi, Li-Huang Su, Yong-Ping Chen · 2022 · Infectious Microbes & Diseases
  33. Spezifische Therapie – neue Medikamente
    Naomi Franziska Lange, Jean‐François Dufour · 2022 · Springer eBooks
  34. Gene Therapy for Diabetes
    Verónica Jiménez, Fátima Bosch · 2024 · Wiley eBooks
  35. Rôle des hépatokines dans le dialogue inter-organes en physiologie et physiopathologie
    Aude Pacheco, Catherine Postic · 2020 · Médecine des Maladies Métaboliques
  36. Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the FGF21 locus
    Ali Bayoumi · 2020 · The Sydney eScholarship Repository (The University of Sydney)
  37. Anti-fibrotic Therapy for Chronic Liver Diseases Review
    Maged Naser, Mohamed M. Naser, Lamia H. Shehata · 2021 · International Journal of Progressive Sciences and Technologies
  38. Impacto da superexpressão do receptor de estrogênio alfa sobre a resistência hepática à insulina e o metabolismo energético do fígado
    Ester S. Alves · 2023 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  39. An Overview of Bone Toxicology
    N. Doyle, Agathe Bédard, Ryan M. Schafbuch, G. Boyd, M. Felx, J. R. White, Aurore Varela · 2023 · Springer eBooks
  40. FGF21 reflects a responsive adipose tissue-liver axis in both cardiometabolic burden and following metabolic surgery
    Marie Patt, Isabel Karkossa, Laura Krieg, Lucas Massier, Kassem Makki, Shirin Tabei, Thomas Karlas, Arne Dietrich, Martin T. Gericke, Michael Stümvoll et al. · 2024 · medRxiv
  41. Endocrine fibroblast growth factors in domestic animals
    Emily J. Brinker, Michael Hardcastle, Keren E. Dittmer, Emily C. Graff · 2024 · Domestic Animal Endocrinology
  42. An Overview of Bone Toxicology
    N. Doyle, Agathe Bédard, Ryan M. Schafbuch, G. Boyd, M. Felx, J. R. White, Aurore Varela · 2024 · Springer eBooks
  43. Evaluating the Effectiveness of Pegbelfermin in MASH ‐Associated Hepatic Fibrosis A Meta‐Analysis and Systematic Review of Randomized Controlled Trials
    Muhammad Shahzil, Fariha Hasan, Syeda Kanza Kazmi, Manesh Kumar Gangwani, Umm-e-Salma Shabbar, Ammad Javaid Chaudhary, Muhammad Ali Khaqan, Muhammad Saad Faisal, Kathy N. Williams, Babu Pappu Mohan et al. · 2025 · JGH Open
  44. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): DISEASE MECHANISMS AND CONTEMPORARY THERAPEUTIC APPROACHES - A LITERATURE REVIEW
    Konrad Strużek, Agnieszka Kwiatkowska, Ewelina Mączka, Wiktor Tracz, Patrycja Świercz, Kinga Teper, Sandra Khiralla-Gawlik, Aleksandra Anna Strzelecka, Aleksandra Ewa Basak · 2025 · International Journal of Innovative Technologies in Social Science
  45. Proteins and the crossroads of diet and type 2 diabetes
    Javad Anjom-Shoae, Tongzhi Wu, Michael Horowitz · 2025 · American Journal of Clinical Nutrition
  46. The value of fibroblast growth factor 21 in health and pathology
    Y. Akhverdyan, E. Papichev, B. V. Zavodovsky, Yu. V. Polyakova, L. E. Seewordova, Рожкова Екатерина Сергеевна · 2025 · Сибирский журнал клинической и экспериментальной медицины
  47. Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease
    Anders Berg Wulff, Anette Varbo, A G Nordestgaard, Børge Grønne Nordestgaard · 2026 · Expert Opinion on Therapeutic Targets
  48. Prise en charge chirurgicale de l’obèse et de l’obèse morbide : conséquences sur la stéatopathie métabolique et sur l’accès à la transplantation hépatique
    Guillaume Lassailly · 2020
  49. Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
    Thaïs Carbinatti · 2024 · theses.fr (ABES)
  50. Baicalein alleviates hepatic lipid metabolism disorders via the PPARα-FGF21-adiponectin axis: Regulating crosstalk between the liver and adipose tissue
    Qingsong Xia, Yu Chen, Pan Shen, Jing Gong, Fu-Er Lu, Hong Chen · 2026 · Journal of Ethnopharmacology
  51. International Utah cardiac recovery symposium (U-CARS) 2025:translational and basic science proceedings
    Joseph R. Visker, Eleni Tseliou, Konstantinos Drosatos, Omar Wever-Pinzon, William Holland, Stavros Drakos · 2026 · Heart Failure Reviews
  52. Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
    Zara Siu Wa Chui, Yaqian Xue, Xiaoping Wu, Aimin Xu · 2026 · Pharmacological Reviews
  53. Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside
    Hak-Keith Leung, Guo-Jeng Tan, Wei‐Kei Wong, Farahani Khamis, Shamsul Mohd Zain, Wah‐Kheong Chan · 2026 · Hepatoma Research
  54. Exerkine-Mediated Inter-Organ Crosstalk and Translational Perspectives in Metabolic Diseases
    Bojun Zhou, Shiyan Zhang, Zhanbo Zhang, Shuman Ran, Haining Guo, Siqi Wang, Hua Meng · 2026 · Current Obesity Reports
  55. Klotho within cardio-renal-hepatic-metabolic health: Integrating mineral metabolism, organ crosstalk, and therapeutic opportunities
    Sanika Taigade, Siddhi Bagwe Parab, Gaurav Doshi · 2026 · Ageing Research Reviews
  56. Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging
    Laura Salmón‐Gómez, Susanne Keipert, Victoria Catalán, Amaia Rodrı́guez, Sara Becerril, Gema Frühbeck, Javier Gómez‐Ambrosi · 2026 · Molecular Biomedicine